Tobira Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
701 Gateway Blvd Ste 300, South San Fran...Phone Number
(650) 741-6625Website
www.tobiratherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Tobira Therapeutics
Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. Tobiras management team has extensive experience in developing and commercializing therapeutics for liver disease and HIV-1. The lead indication for CVC is non-alcoholic steatohepatitis, or NASH, for which Tobira plans to begin a Phase 2 clinical trial in the second half of 2006. The company believes there are no other product candidates in development for NASH that target the immuno-inflammatory pathways responsible for fibrosis. CVC also is Phase 3-ready in HIV-1 infection with potential as the backbone in a fixed-dose combination therapy. CVC is a once-daily pill with a safety and tolerability profile that has been established to date in 55Read more
Tobira Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tobira Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Tobira Therapeutics is spiking on competitors!
Check if Tobira Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Tobira Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Tobira Therapeutics recently announced quarterly report
Click to see if Tobira Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Tobira Therapeutics launches new products
Funding: Get notified immidiatlly once Tobira Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Tobira Therapeutics
Recommended Actions
Reach out to Masked Content who joined Tobira Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Tobira Therapeutics
Compare insights from companies similar to Tobira Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tobira Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tobira Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tobira Therapeutics.
Tobira Therapeutics Tech Stack
A closer look at the technologies used by Tobira Therapeutics
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tobira Therapeutics
Sign Up For FreeTo access detailed company insights
Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. T... Read More
